Diagnosticos da America SA (DASA), Laboratorio Clinico Delboni Auriemo SA, Brazil
Review Article
Seroconversion for SARS-CoV-2 in Rheumatic Patients on Synthetic and Biologics Disease Modifying Anti-Rheumatic Drugs in São Paulo, Brazil
Author(s): Santana FM, Lopes JB, Perez MO, Campana G, Levi JE, Lopes FPPL, Gebara OE, Cobra JF and Figueiredo CP*
Introduction: There is a lack of information on how immunomodulatory drugs for autoimmune rheumatic diseases (ARDs) impair humoral immune
response following SARS-CoV-2 exposure.
Methods: A prospective study was performed with ARD patients on synthetic or biologic DMARDs (sDMARDs or bDMARDs) classified into three
groups (antimalarial monotherapy, antimalarial plus bDMARD, antimalarial plus sDMARD) and a fourth group (control). All patients underwent
a clinical baseline interview, anti-SARS-CoV-2 IgG/IgM tests at baseline and three months later, monitored for incident respiratory symptoms at
follow-up, with rRT-PCR in suspected cases.
Results: One hundred patients were included. Fewer than half who turned IgG positive (42.8%) remained asymptomatic. All three positive rRT-PCR
patients showed seroconver.. Read More»
DOI:
10.37421/1747-0862.2021.s1.482
Molecular and Genetic Medicine received 3919 citations as per Google Scholar report